SCHEMBL5644137

SCHEMBL5644137

Cc1ccc(C)c(COc2ccccc2CO)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.45
PTGER1 P34995 1/20 0.43
PTGER4 P35408 1/20 0.43
PTGER3 P43115 1/20 0.43
PTGER2 P43116 1/20 0.43
MAPT P10636 3/20 0.42
LMNA P02545 2/20 0.42
TACR1 P25103 1/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TNF P01375 1/20 0.40
TSHR P16473 1/20 0.40
CYP19A1 P11511 1/20 0.40
SLC1A5 Q15758 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5645243 0.85 CDK4 (0.54) PTGDR2CDK4CCND1KDM4ESLC1A5
SCHEMBL11079744 0.83 GAA (0.49) PTGDR2MAPTLMNATACR1GAA
SCHEMBL2557287 0.80 LIPE (0.55) PTGDR2PTGER1PTGER4PTGER3PTGER2
SCHEMBL5644007 0.78 SLC1A5 (0.54) PTGER1PTGER4PTGER3PTGER2MAPT
SCHEMBL5838420 0.78 ALDH1A1 (0.57) PTGDR2PTGER1HTTKDM4EKMT2A
SCHEMBL27814043 0.77 SMN1; SMN2 (0.51) PTGDR2MAPTLMNAHTTTDP1
SCHEMBL8592978 0.76 SMN1; SMN2 (0.54) PTGDR2MAPTLMNAHTTTDP1
SCHEMBL6212452 0.76 PTGER1 (0.60) PTGER1PTGER4PTGER3PTGER2MAPT
SCHEMBL23680050 0.76 CDK4 (0.56) PTGDR2PTGER1PTGER4PTGER3PTGER2
SCHEMBL92914 0.75 TAAR1 (0.56) HTTTDP1GAAKDM4ETNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217697-B2 Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-05-15 US disclosed
US-20040176308-A1 Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor KISSEI PHARMACEUTICAL CO., LTD. (JP) 2004-09-09 US disclosed
EP-1400529-A1 GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE THEREFOR Kissei Pharmaceutical Co., Ltd. (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176308-A1 Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor SLC5A1, SLC5A2, UGGT1 PTGDR2 1181/4885PTGER1 282/4885PTGER4 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.